Compare ResMed Inc. (RMD) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Boston Beer Company Inc — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Boston Beer Company Inc trades at $170.51 (market cap $1.76B). The key difference: ResMed Inc. is far larger — about 18.1× Boston Beer Company Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Boston Beer Company Inc for 59 Days on average.
| RMD | SAM | |
|---|---|---|
Market Cap | $31.89B | $1.76B |
Volume | 618,314 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $277.88 | $260.05 |
52-Week Low | $182.82 | $161.08 |
Typical Hold Time | 51 Days | 59 Days |
Enterprise Value | $31.24B | $1.53B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Boston Beer Company (SAM) trades at $170.51, up 1.4% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a P/E of 22.66 and negative net margin of -3.64%, though operating cash flow remains strong at $270M. Recent news highlights brand innovation including new cocktail products and marketing partnerships, while analyst consensus leans heavily toward Hold (71.87%) with a $204.44 price target.
SAM faces headwinds from declining alcohol consumption and cost pressures, but brand investments and new product launches offer growth potential. The stock trades near support at $169 with upside to analyst targets, though execution risks and margin pressure require monitoring. Current valuation appears reasonable relative to historical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
